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a b s t r a c t
Introduction: It is generally recognized that a wide variety of morphogens and growth factors bind to the
glycosaminoglycans (GAG) of proteoglycans (PG) to affect their bioavailability to ligands. Many growth
factors involving in osteogenic differentiation require the GAG side chains to facilitate their interaction to
the cell surface receptors and the biosynthesis of osteogenic proteins. The objective of this study is to
investigate the secretion of GAG from MC3T3-E1 pre-osteoblasts of a murine bone calvaria during the
osteogenic differentiation.
Methods: When MC3T3-E1 cells were cultured in the differentiation medium (DM) containing bone
morphogenetic protein (BMP)-2, the alkaline phosphatase activity, calcium content and the amount of
basic ﬁbroblast growth factor (bFGF)- or BMP-2-bound sulfated GAG were determined. Moreover, the
disaccharide analysis of the GAG was performed.
Results: When MC3T3-E1 cells were cultured in the differentiation medium (DM) containing bone
morphogenetic protein (BMP)-2, the alkaline phosphatase activity and calcium content were signiﬁ-
cantly enhanced compared with those of the BMP-2-free DM and normal medium with or without BMP-
2. Signiﬁcantly higher amount of GAG secreted was detected for cells cultured in the DM containing BMP-
2, in contrast to other culture conditions. The GAG secreted had an afﬁnity for BMP-2 and basic ﬁbroblast
growth factor (bFGF). The disaccharide analysis of GAG demonstrated that the percentage of DHexA
a1,4GlcNSO3 and DHexA (2-OSO3) a1,4GlcNSO3 increased, but that of DHexA a1,4GlcNSO3(6-OSO3)
decreased (DHexA: unsaturated uronic acid residue, GlcNSO3: N-sulfated glucosamine, DHexA (2-OSO3):
unsaturated uronic acid 2-sulfate residue, GlcNSO3(6-OSO3): N-sulfated glucosamine 6-sulfated).
Conclusion: It was found that the osteogenic differentiation allowed cells to enhance the secretion of
GAG with an afﬁnity for BMP-2 and bFGF.
© 2018, The Japanese Society for Regenerative Medicine. Production and hosting by Elsevier B.V. This is
an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/
4.0/).
1. Introduction
Glycosaminoglycans (GAG) are linear and long-chain carbohy-
drates of repeating disaccharide units with different positioned
sulfate groups. Proteoglycans (PG) are generally composed of a core
protein and the GAG, which are covalently bound to the core pro-
tein via a tetrasaccharide linkage. There are different types of the
GAG: chondroitin sulfate, dermatan sulfate, heparan sulfate, and
heparin. It is generally recognized that a wide variety of morpho-
gens and growth factors bind to the GAG of PG to affect their
bioavailability to ligands [1e6]. Many growth factors involving in
osteogenic differentiation require the GAG side chains to facilitate
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their interaction to the cell surface receptors and the biosynthesis
of osteogenic proteins [7,8]. For example, basic ﬁbroblast growth
factor (bFGF) is secreted into the extracellular matrix by matured
osteoblasts and acts to regulate the bone formation [9]. It stimu-
lates the proliferation of various types of bone cells, including bone
marrow stromal cells and osteoblast-like cell lines [10,11]. More-
over, it is well known that bone morphogenetic protein (BMP)-2 of
osteogenic factor and has a binding ability for GAG. It is demon-
strated that heparan sulfate modulates the osteogenic bioactivity of
BMP-2 by the sequestration from the cell surface receptor [8]. Such
many papers have been reported on the GAG properties to modu-
late the functions of growth factors. However, little has been re-
ported on the association between the GAG secretion from the cells
and afﬁnity of the osteogenic proteins with the GAG during the
osteogenic differentiation from the immature stage.
In this paper, the GAG secretion from the MC3T3-E1 cells of a
murine bone calvaria pre-osteoblast was investigated during their
osteogenic differentiation. The cells were osteogenically differen-
tiated by BMP-2 and the afﬁnity of GAG secreted for BMP-2 and
bFGF was evaluated. To further obtain the chemical structural in-
formation containing bonding positions of the sulfate groups, we
examined the composition ratio of repeated disaccharide units of
GAG secreted with a disaccharide analysis.
2. Materials and methods
2.1. Materials
bFGF was kindly supplied by Kaken Pharmaceutical Co., Ltd.
(Tokyo, Japan). BMP-2 was purchased from R&D Systems, Inc.
(Minneapolis, USA). Other chemicals were obtained from Nacalai
Tesque, Inc., Kyoto, Japan and Wako Pure Chemical Industries, Ltd.,
Osaka, Japan, and used without further puriﬁcation.
2.2. Cell culture and osteogenic differentiation
MC3T3-E1 cells of a murine bone calvaria pre-osteoblast were
cultured in the normal medium (NM) consisting of a-Minimum
Essential Medium (aMEM, Invitrogen Corp., California, USA) with
10 vol % fetal calf serum (FCS, HyClone Laboratories, Inc., Logan,
USA) and antibiotics (100 U/ml penicillin G and 100 mg/ml strep-
tomycin (Sigma Aldrich Corp., St. Louis, USA)) at 37 C in a hu-
midiﬁed atmosphere with 5% CO2 -95% air at an initial density of
6  103 cells per cm2. After 2 days culture, the medium was
replaced with the differentiation medium (DM) which is the NM
supplemented with 10 nM dexamethasone, 25 mg/ml L-ascorbic
acid and 10 mM b-glycerophosphate (Sigma Aldrich Corp., St. Louis,
USA). Then, the cell was cultured further for 7 days while the DM
was changed every 3e4 days.
2.3. Alkaline phosphatase and calcium assay
Alkaline phosphatase (ALP) enzyme activity was assayed with a
commercial kit (LabAssay ALP;Wako Pure Chemical Industries, Ltd.,
Osaka, Japan) on the basis of the absorbance measurement of a p-
nitrophenol product. Brieﬂy, MC3T3-E1 cells were rinsed twice
with PBS, freeze-thawed, and ﬁnally incubated in 70 ml/cm2 of
aqueous solution containing sodium dodecyl sulfate (SDS, 0.2 mg/
ml), NaCl (3 M), and sodium citrate (0.3 M) for 1 h at 37 C for cell
lysis. Next, 20 ml of cell lysate was mixed with 100 ml of 6.7 mM p-
nitrophenyl phosphate aqueous solution, followed by incubation
for 15 min at 37 C. After mixing 1 ml of 20 mM NaOH aqueous
solution, the absorbance of the solution mixture was measured at
405 nmwith a spectorophotometer (VERSAmax; Molecular Devices
Japan KK, Tokyo, Japan) to assess the ALP activity.
Cells were incubated in 1 ml of 0.5 N HCl solution by shaking for
4 h at 4 C. The amount of calcium in the HCl solution obtained was
determined with a commercial kit (Calcium C-test Wako; Wako
Pure Chemical Industries, Ltd., Osaka, Japan). Brieﬂy, 10 ml of cell
lysate was mixed with 1 ml of 0.88 M monoethanolamine aqueous
solution. After mixing 100 mL of 69 mM 8-hydroxyquinoline and
0.63 mM o-cresolphthalein complexone aqueous solution, the so-
lution mixture was allowed to stand for 5 min. The absorbance of
the solution mixture was measured at 570 nm with the spec-
trometer to assess the calcium amount. Experiment was done
independently 3 times for each sample.
2.4. Determination of sulfated GAG
The determination of sulfated GAG was performed according to
themethod reported [12]. Brieﬂy,16mg of 1, 9-dimethylmethylene
blue (DMMB) was dissolved in 5 ml ethanol. Then, 2 g of sodium
formate and 2 ml of 98 vol % formic acid aqueous solution were
added to the DMMB ethanol solution, and the ﬁnal volume was
adjusted to 100 ml with double distilled water (DDW). The culture
supernatant of cells (25 ml) was mixed with 225 ml of DMMB dye
solution and the absorbance of solution mixture was measured at
525 nm with a spectorophotometer (VERSAmax; Molecular De-
vices Japan KK, Tokyo, Japan). Shark chondroitin sulfate A sodium
salt (Sigma Aldrich Corp., St. Louis, USA) was used to prepare the
standard curve.
2.5. Determination of bFGF- or BMP-2-bound sulfated GAG
Heparin sepharose (5 ml, GE Healthcare UK Ltd., UK) was
washed twice with ten-times volume of phosphate buffer solution
(PBS, 10 mM Na2HPO4 and NaH2PO4, pH 7.0) in a tube and mixed
with 200 ml PBS containing 10 mg of bFGF or BMP-2 for 10 min at
room temperature. After washed twice with 200 ml of PBS, bFGF-
or BMP-2-heparin sepharose was mixed with 200 ml of the culture
medium obtained. Next 25 ml of the supernatant was mixed with
225 ml of the DMMB dye solution, the absorbance of solution
mixture was measured at 525 nm with a spectorophotometer
(VERSAmax; Molecular Devices Japan KK, Tokyo, Japan). Shark
chondroitin sulfate A sodium salt (Sigma Aldrich Corp., St. Louis,
USA) was used to prepare the standard curve. The GAG bound to
bFGF or BMP-2 was determined by subtraction the absorbance of
culture medium after treatment with bFGF- or BMP-2-heparin
sepharose from the one before treatment with bFGF- or BMP-2-
heparin sepharose.
2.6. Disaccharide analysis of sulfated GAG
The culture medium obtained was ﬁltered with the centrifugal
ﬁlter of 10 000 molecular weight cut-off, and then treated with
heparin lyase I, II, and III (Heparinase and Heparitinase (Seikagaku
Corporation, Tokyo, Japan) at 0.1 unit each in 30 ml of CH3COONa
(20 mM, pH 7.0), Ca(CH3COO)2 (2 mM) and 0.2 wt% BSA aqueous
solution) and incubated at 37 C for 1 h. The products were puriﬁed
with BlotGlyco® (Sumitomo Bakelite Co., Ltd, Tokyo, Japan) to
prepare the sample of disaccharides. Disaccharide analysis was
performed on a high performance liquid chromatography (HPLC)
system (ELITE Lachrom; Hitachi High-Technologies Corporation,
Tokyo, Japan). Solutions A and B for the HPLC separation contained
50mMHCOONH4 (pH 4.4) and acetonitrile, respectively. Separation
was performed on the column (TSK-GEL Amide-80; Tosoh Corpo-
ration, Yamaguchi, Japan) at 400 ml/min ﬂow rate using 20 vol %
solution A, followed by a linear gradient from 0 to 80 min of
20e41.7 vol % solution A.
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2.7. Statistical analysis
All assays were performed in triplicate. All data were expressed
as means ± standard deviation. The statistical analysis was per-
formed by the independent sample t tests and p < 0.05 was
accepted to be signiﬁcant.
3. Results
3.1. Osteogenic differentiation of MC3T3-E1 cells
Fig. 1 shows the ALP activity and Ca content of MC3T3-E1 cells 7
days after culturing in DM and NM containing 0 and 100 ng/ml of
BMP-2. The MC3T3-E1 cells cultured in the DM containing 100 ng/
ml of BMP-2 exhibited signiﬁcantly higher levels of ALP activity and
Ca content than those cultured in other culture conditions. Osteo-
genic differentiation culture without BMP-2 showed signiﬁcantly
higher levels of ALP activity than the normal culture.
3.2. Secretion of GAG
Fig. 2 showsGAG in conditionedmediumofMC3T3-E1 cells 7 days
after culturing in DM and NM containing 0 and 100 ng/ml of BMP-2.
MC3T3-E1 cells cultured in the DM with and without 100 ng/ml of
BMP-2 exhibited signiﬁcantly higher amount of GAG than those
cultured in NM. Moreover, GAG in conditionedmedium of MC3T3-E1
cells cultured in the DM increased over time (data not shown).
Fig. 3 shows bFGF- and BMP-2-bound GAG in conditioned me-
dium of MC3T3-E1 cells 7 days after culturing in DM and NM
containing 0 and 100 ng/ml of BMP-2. The GAG secreted from
MC3T3-E1 cells cultured in the DM with or without BMP-2 had an
afﬁnity for bFGF and BMP-2.
Fig. 4 shows the disaccharide analysis results of sulfated GAG
secreted from MC3T3-E1 cells 7 days after culturing in DM con-
taining 100 ng/ml of BMP-2 and NM. The disaccharide analysis of
GAG demonstrated that the percentage of DHexA a1,4GlcNSO3 and
DHexA (2-OSO3) a1,4GlcNSO3 increased, but that of DHexA
a1,4GlcNSO3(6-OSO3) decreased (DHexA: unsaturated uronic acid
residue, GlcNSO3: N-sulfated glucosamine, DHexA (2-OSO3): un-
saturated uronic acid 2-sulfate residue, GlcNSO3(6-OSO3): N-
sulfated glucosamine 6-sulfated).
4. Discussion
The present study demonstrates that MC3T3-E1 cells secreted
GAG accompanied with the osteogenic differentiation. The GAG
secreted from cells cultured in the DM containing BMP-2 had a
higher afﬁnity for BMP-2 and bFGF than those cultured in the BMP-
2-free DM. The afﬁnity was signiﬁcantly high comparedwith that of
cells cultured in the NM with or without BMP-2.
Song et al. demonstrate that the proliferation and mineraliza-
tion of primary rat calvarial osteoblasts were enhanced by the
exogenous treatment of bFGF, and syndecan-4, a type of heparin
sulfate proteoglycans (HSPG), was upregulated by the bFGF treat-
ment [13]. Zehe et al. also report that HSPG are required for the
bFGF secretion from mammalian cells [14]. Secretion of PG bearing
GAG is normally accompanied with the growth factor secretion
from cells. The researches indicate that GAG is generally involved in
growth factor. In addition, it is well recognized that bFGF and BMP-
2 involving the osteogenic differentiation can bind with heparin
and heparan sulfate to stabilize the biological activities [15e20].
Levenstein et al. report that HSPG secreted from human embryonic
stem (ES) cells stabilizes bFGF [21]. Moreover, the binding needs the
subsequent intracellular signaling [22]. Considering the in vivo
stability of growth factors secreted into the body tissue, it will
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Fig. 1. (a) ALP activity and (b) Ca content of MC3T3-E1 cells 7 days after culturing in DM and NM containing 0 (,) and 100 ng/ml of BMP-2 (-). *, P < 0.05; signiﬁcant against the






















Fig. 2. Amount of sulfated GAG secreted from MC3T3-E1 cells 7 days after culturing in
DM and NM containing 0 (,) and 100 ng/ml of BMP-2 (-). *, P < 0.05; signiﬁcant
against the value of cells cultured in NM at the corresponding BMP-2 concentration.
y, P < 0.05; signiﬁcant against the value of cells cultured in NM at the corresponding
BMP-2 concentration.
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enzymatic degradation. Therefore, it is likely that the living body
should provide some manners to increase the in vivo stability. As a
natural stabilizer, the sulfated GAG must be suitable. With the
differentiation process of cells, growth factors are secreted. In
addition, it is highly conceivable that the cells simultaneously
produce GAG to stabilize or enhance the biological functions of
growth factors, resulting in promoted the growth factor-based cell
differentiation.
The disaccharide analysis was performed to examine the
chemical structure of GAG secreted from the cells. The analysis
demonstrated that the percentage of DHexA a1,4GlcNSO3 and
DHexA (2-OSO3) a1,4GlcNSO3 increased, whereas that of DHexA
a1,4GlcNSO3(6-OSO3) decreased.
Turnbull et al. demonstrate that oligosaccharides derived from
heparin sulfate with a high afﬁnity for bFGF contain DHexA (2-
OSO3) al,4GlcNSO3 more than those with medium and low afﬁn-
ity for bFGF. Oppositely, oligosaccharides derived from heparin
sulfate with a low afﬁnity for bFGF contain DHexA a1,4GlcNAc(6-
OSO3) and DHexA a1,4GlcNSO3(6-OSO3) more than those with
medium and high afﬁnity for bFGF [16]. In addition, bFGF binds to
heparin and to selectively glucosaminyl 6-O-desulfated heparin,
but poorly to iduronosyl 2-O-desulfated heparin, and 2-O-sulfate
groups thus are essential to the interaction, whereas 6-O-sulfates
are not required nor do they interfere with the bFGF binding [17].
Moreover, it is well recognized that the sulfate sequences of hep-
arin and heparan sulfate require iduronosyl 2-O-sulfate groups to
bind bFGF and both iduronosyl 2-O-sulfate groups and glucosa-
minyl 6-O-sulfate groups to form trimeric signaling complex with
bFGF and FGF receptor, resulting in activating mitogenicity and
angiogenesis of Swiss mouse 3T3 ﬁbroblasts and Chinese hamster
ovary cell line 677 (CHO677) [22,23]. It is demonstrated that a high
content of 2-O-sulfate groups in uronate residues and 6-O-sulfate
groups in N-sulfated glucosamine residues of heparin are required
for activation of both FGF-1 and FGF-2 [24,25]. In contrast, 6-O-
desulfated heparins had no effect on the proliferation of human
neural stem/progenitor cells [26]. This implies that different types
of cells might require the different sulfation patterns of heparin
necessary for their proliferation. Considering the research ﬁndings,
it is likely that the GAG secreted from MC3T3-E1 cells cultured in
the DM to bind and stabilize growth factors rather than to directly
promote their biological activity. It is apparent that the GAG



























































Fig. 3. (a) Amount of bFGF-bound and (b) BMP-2-bound sulfated GAG secreted from MC3T3-E1 cells 7 days after culturing in DM and NM containing 0 (,) and 100 ng/ml of BMP-2
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Fig. 4. Disaccharide analysis of sulfated GAG secreted from MC3T3-E1 cells 7 days after culturing in DM containing 100 ng/ml of BMP-2 (,) and NM (-). *, P < 0.05; signiﬁcant
against the value of cells cultured in NM at the corresponding disaccharide. DHexA: unsaturated uronic acid residue, GlcNAc: N-acetyl glucosamine, GlcNAc(6-OSO3): N-acetyl
glucosamine 6-sulfated, GlcNSO3: N-sulfated glucosamine, GlcNSO3(6-OSO3): N-sulfated glucosamine 6-sulfated, DHexA (2-OSO3): unsaturated uronic acid 2-sulfate residue.
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sulfate groups in uronate residues and less 6-O-sulfate groups in
glucosamine than those cultured in the NM. Taken together, we can
say with certainty that upon secreting growth factors for differ-
entiation, cells simultaneously produce sulfated GAG to allow the
factors to enhance the in vivo stability for promotion of their bio-
logical functions.
5. Conclusion
This study has investigated the secretion of glycosaminoglycans
(GAG) from MC3T3-E1 pre-osteoblasts of a murine bone calvaria
during the osteogenic differentiation. When MC3T3-E1 cells were
cultured in the differentiation medium (DM) containing bone
morphogenetic protein (BMP)-2, signiﬁcantly higher amount of
GAG secreted was detected for the cells compared with those
cultured in the BMP-2-free DM and normal medium with or
without BMP-2. The GAG secreted had an afﬁnity for BMP-2 and
basic ﬁbroblast growth factor (bFGF). The disaccharide analysis of
GAG demonstrated that the percentage of DHexA a1,4GlcNSO3 and
DHexA (2-OSO3) a1,4GlcNSO3 increased, but that of DHexA
a1,4GlcNSO3(6-OSO3) decreased. It was found that the osteogenic
differentiation allowed cells to enhance the secretion of GAG with
an afﬁnity for BMP-2 and bFGF.
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